Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Vistin Pharma ASA : Key information for the subsequent repair issue

Posted on: 22 Mar 18

Reference is made to the stock exchange notice from Vistin Pharma ASA earlier today, 22 March 2018, regarding a subsequent repair issue of approximately NOK 50 million. Key information for the subsequent repair issue is described below.


Date on which the terms and conditions of the subsequent repair issue were announced: 22 March 2018

Last day including right: 22 March 2018

Ex-date: 23 March 2018

Record Date: 26 March 2018

Date of approval: 9 May 2018

Maximum number of new shares: 4,464,286

Subscription price: NOK 11.20

Will the rights be listed - yes/no: No

Other information: The subsequent repair issue is subject to approval by the annual general meeting of Vistin Pharma ASA and approval and publication of a prospectus, expected to take place on or about 11 May 2018.

This information is published in accordance with the requirements of the Continuing Obligations.


Last updated on: 24/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.